1236357-60-0

Basic information

• Product Name: 1-bromo-4-(3,3-difluorocyclobutyl)benzene
• Synonyms: 1-bromo-4-(3,3-difluorocyclobutyl)benzene
• CAS NO: 1236357-60-0
• Molecular Weight: 247.082
• Mol File: 1236357-60-0.mol

Chemical Properties

• CAS DataBase Reference: 1-bromo-4-(3,3-difluorocyclobutyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-4-(3,3-difluorocyclobutyl)benzene(1236357-60-0)
• EPA Substance Registry System: 1-bromo-4-(3,3-difluorocyclobutyl)benzene(1236357-60-0)

Safety Data

• Hazardous Substances Data: 1236357-60-0(Hazardous Substances Data)

Usage

Chemical structure

The compound consists of a benzene ring with a bromine atom attached at the 1 position and a 3,3-difluorocyclobutyl group attached at the 4 position.

Derivative of benzene

It is a derivative of benzene, which is a fundamental aromatic hydrocarbon with a ring structure.

Fluorine atoms

The cyclobutyl group contains fluorine atoms, which can influence the compound's reactivity and properties.

Organic synthesis

It is used in organic synthesis, which is the chemical synthesis of carbon-containing compounds.

Research applications

The compound has potential applications in research, particularly in the study of chemical reactions and mechanisms.

Agrochemical industry

The compound could also be used in the agrochemical industry, which focuses on the development of chemical products for agriculture, such as pesticides and fertilizers.

Reactivity

Due to the presence of bromine and fluorine atoms, the compound may exhibit interesting reactivity, making it suitable for various chemical processes and applications.

Properties

The specific properties of 1-bromo-4-(3,3-difluorocyclobutyl)benzene, such as its melting point, boiling point, and solubility, can be influenced by the presence of bromine and fluorine atoms in the molecule.

Safety considerations

As with any chemical compound, it is essential to consider safety precautions when handling and using 1-bromo-4-(3,3-difluorocyclobutyl)benzene, particularly due to its potential reactivity and applications in various industries.

Upstream product

• 202289-38-1 (bis-(2-methoxyethyl)amino)sulfur trufluoride 
• 254892-91-6 3-(4-bromophenyl)cyclobutanone 
• 1122-91-4 4-bromo-benzaldehyde 
• 254892-87-0 3-(4-bromophenyl)-2,2-dichlorocyclobutan-1-one 
• 2039-82-9 1-bromo-4-ethenyl-benzene 

Relevant articles and documents

PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS

The present disclosure provides processes for preparing 1,2,3-triazole-4-carboxylic acid related compounds of formulae (I) and (II) via a Suzuki coupling reaction. The Suzuki coupling reaction is achieved by coupling a compound of formula (IV), a boron-containing derivative of 1,2,3-triazole-4-carboxylate, with a cycloalkyl phenyl halide or sulfonate of formula (V).

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

OXAZOLIDINONE HYDROXAMIC ACID COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

This invention pertains generally to treating bacterial infections using organic compounds of Formula I. In certain aspects, the invention pertains to treating infections caused by Gram-negative bacteria. (I) wherein X, Y, R1, R2, R3, R4 and R5 and defined herein.

4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention provides compounds of Formula (I), wherein R1, R2a, R2b, R3, m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.

4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES

The invention provides compounds of the general Formula (I) where R1, R2, and A are defined herein, as well as the preparation, compositions and uses thereof.